Inclusion Criteria

DISEASE CHARACTERISTICS: Histologically proven osteosarcoma previously treated with
standard chemotherapy agents (methotrexate, doxorubicin/cisplatin, ifosfamide) Active
metastatic disease following chemotherapy At least 1 bidimensionally measurable lesion
located in a nonirradiated area CT scan lesion at least 20 mm in at least 1 diameter
Clinically measurable lesion at least 20 x 20 mm No symptomatic or known brain or
leptomeningeal involvement

PATIENT CHARACTERISTICS: Age: 12 and over Performance status: WHO 0-1 Life expectancy: At
least 3 months Hematopoietic: Neutrophil count at least 1,500/mm3 Platelet count at least
100,000/mm3 Hepatic: Bilirubin no greater than upper limit of normal (ULN) Alkaline
phosphatase no greater than ULN OR Alkaline phosphatase liver fraction and 5'-nucleotidase
no greater than ULN AST/ALT less than 2.5 times ULN Albumin greater than 25 g/L No
clinically significant liver disease Renal: Creatinine no greater than 1.5 mg/dL OR
Creatinine clearance at least 40 mL/min Cardiovascular: No congestive heart failure or
angina pectoris even if medically controlled No myocardial infarction within past year No
uncontrolled arterial hypertension No arrhythmias Other: Not pregnant or nursing Fertile
patients must use effective contraception No history of other malignancy except basal cell
carcinoma or carcinoma in situ of the cervix No other serious illness or medical
conditions (e.g., history of significant neurological or psychiatric disorders, active
infection) No concurrent grapefruit consumption on a regular basis

PRIOR CONCURRENT THERAPY: Biologic therapy: Recovered from prior immunotherapy No
concurrent prophylactic filgrastim (G-CSF) or sargramostim (GM-CSF) Chemotherapy: See
Disease Characteristics At least 4 weeks since prior chemotherapy and recovered No other
concurrent local or systemic chemotherapy Endocrine therapy: Not specified Radiotherapy:
Recovered from prior radiotherapy No concurrent palliative or primary radiotherapy
Surgery: Not specified Other: At least 30 days since other prior investigational drugs No
other concurrent investigational drugs No concurrent participation in another clinical
trial